{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:38:49Z","timestamp":1793252329159,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jaci.2021.12.772","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T07:39:04Z","timestamp":1640245144000},"page":"1683-1690.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria"],"prefix":"10.1016","volume":"149","author":[{"given":"Sabine","family":"Altrichter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Staubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Pasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik S.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Siebenhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-481X","authenticated-orcid":false,"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.12.772_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.12.772_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A\u00a0GA(2)LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.12.772_bib3","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.12.772_bib4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1398-9995.2008.01920.x","article-title":"The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings","volume":"64","author":"Mlynek","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.12.772_bib5","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaip.2019.10.046","article-title":"Sexual functioning is frequently and markedly impaired in female patients with chronic spontaneous urticaria","volume":"8","author":"Ertas","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.772_bib6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.jaci.2016.05.026","article-title":"Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria","volume":"138","author":"Koch","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.772_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pharmthera.2012.06.005","article-title":"Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions","volume":"135","author":"Kiwamoto","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaci.2021.12.772_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126219","article-title":"Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis","volume":"4","author":"Youngblood","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2021.12.772_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.12.772_bib10","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.772_bib11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.772_bib12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/jid.2014.512","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.12.772_bib13","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.772_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic\u00a0autoimmune urticaria with omalizumab","volume":"122","author":"Kaplan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.772_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.772_bib16","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.772_bib17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMc2016395","article-title":"Benralizumab for chronic spontaneous urticaria","volume":"383","author":"Bernstein","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.12.772_bib18","article-title":"The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: real-life data","volume":"32","author":"Salman","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2021.12.772_bib19","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jaip.2018.12.025","article-title":"Efficacy and safety of omalizumab (Xolair) for cholinergic urticaria in patients unresponsive to a double dose of antihistamines: a randomized mixed double-blind and open-label placebo-controlled clinical trial","volume":"7","author":"Gastaminza","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2021.12.772_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WOX.0b013e3181bb965f","article-title":"Eosinophils in chronic urticaria: supporting or leading actors?","volume":"2","author":"Asero","year":"2009","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2021.12.772_bib21","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jaci.2020.03.005","article-title":"The role of eosinophils in chronic spontaneous urticaria","volume":"145","author":"Altrichter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.772_bib22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1398-9995.2008.01920.x","article-title":"The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings","volume":"64","author":"Mlynek","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.12.772_bib23","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1111\/all.13878","article-title":"Diagnosis and treatment of chronic inducible urticaria","volume":"74","author":"Maurer","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.12.772_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/ced.12547","article-title":"Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism","volume":"40","author":"Schoepke","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.12.772_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000492970","article-title":"Fric Test revisited: a suggestion for a new scoring system and its correlation with Urticaria Control Test and Dermatology Life Quality Index","volume":"178","author":"Can","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2021.12.772_bib26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2017.01.042","article-title":"Omalizumab is effective in symptomatic dermographism\u2014results of a randomized placebo-controlled trial","volume":"140","author":"Maurer","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.12.772_bib27","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA(2)LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.12.772_bib28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jdermsci.2014.04.007","article-title":"Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria","volume":"75","author":"Altrichter","year":"2014","journal-title":"J Dermatol Sci"}],"updated-by":[{"DOI":"10.1016\/j.jaci.2022.07.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000}}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921026828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921026828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T01:13:37Z","timestamp":1665710017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921026828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0091674921026828"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.12.772","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jaci.2022.07.006","asserted-by":"object"}]},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.12.772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}